ArticleJournal of clinical microbiology2015
Buffer AVL Alone Does Not Inactivate Ebola Virus in a Representative Clinical Sample Type.
Article in Journal of clinical microbiology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 49 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
49 citing papers in PubMed, 76 citations in OpenAlex.
- Genomics in containment: BSL-4-compatible workflows enable high-resolution genomic and transcriptomic analyses of Risk Group 4 viruses.iScience · 2026Article
- Review
- Evaluation of beta-propiolactone and AVL-ethanol inactivation protocols for highly pathogenic avian influenza virus in allantoic fluid and cell culture.Applied and environmental microbiology · 2026Article
- Inactivation of Ebola, Nipah, and Lassa viruses in tissue using neutral buffered formalin, MagMAX lysis/binding solution, or TriPure isolation reagent.Scientific reports · 2025Article
- Standardized Diagnostic Assays for Omsk Hemorrhagic Fever Virus.Pathogens (Basel, Switzerland) · 2025Article
- Evaluating viral inactivation in the liquid waste stream from a viral total nucleic acid extraction kit for safe disposal.Biosafety and health · 2025Article
- Thermal tolerance and inactivation of Ebola virus.Virologica Sinica · 2025Article
- Approaches for inactivating highly pathogenic avian influenza H5N1 cattle isolate for safe containment level 2 laboratory practices.Applied and environmental microbiology · 2025Article
- Virucidal Approaches for Hemorrhagic Fever Viruses.Viruses · 2025Review
- Successful Inactivation of High-Consequence Pathogens in PrimeStore Molecular Transport Media.Viruses · 2025Article
- Enhancing safety of rapid and accurate malaria diagnosis in patients at risk for viral haemorrhagic fever.Malaria journal · 2025Article
- Validation of Marburg Virus Inactivation by AVL Buffer.Methods in molecular biology (Clifton, N.J.) · 2025Article
- Inactivation Validation of Ebola, Marburg, and Lassa Viruses in AVL and Ethanol-Treated Viral Cultures.Viruses · 2024Article
- Heat Inactivation of Nipah Virus for Downstream Single-Cell RNA Sequencing Does Not Interfere with Sample Quality.Pathogens (Basel, Switzerland) · 2024Article
- Reverse Genetics Systems for Filoviruses.Methods in molecular biology (Clifton, N.J.) · 2024Article
- Art of the Kill: Designing and Testing Viral Inactivation Procedures for Highly Pathogenic Negative Sense RNA Viruses.Pathogens (Basel, Switzerland) · 2023Article
- Establishment of an Inactivation Method for Ebola Virus and SARS-CoV-2 Suitable for Downstream Sequencing of Low Cell Numbers.Pathogens (Basel, Switzerland) · 2023Article
- Diagnostics of Ebola virus.Frontiers in public health · 2023Review
- Evaluation of Five Buffers for Inactivation of Monkeypox Virus and Feasibility of Virus Detection Using the Panther FusionViruses · 2022Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Rapid inactivation of Ebola virus (EBOV) is crucial for high-throughput testing of clinical samples in low-resource, outbreak scenarios. The EBOV inactivation efficacy of Buffer AVL (Qiagen) was tested against marmoset serum (EBOV concentration of 1 × 10(8) 50% tissue culture infective dose per milliliter [TCID50 · ml(-1)]) and murine blood (EBOV concentration of 1 × 10(7) TCID50 · ml(-1)) at 4:1 vol/vol buffer/sample ratios. Posttreatment cell culture and enzyme-linked immunosorbent assay (ELISA) analysis indicated that treatment with Buffer AVL did not inactivate EBOV in 67% of samples, indicating that Buffer AVL, which is designed for RNA extraction and not virus inactivation, cannot be guaranteed to inactivate EBOV in diagnostic samples. Murine blood samples treated with ethanol (4:1 [vol/vol] ethanol/sample) or heat (60°C for 15 min) also showed no viral inactivation in 67% or 100% of samples, respectively. However, combined Buffer AVL and ethanol or Buffer AVL and heat treatments showed total viral inactivation in 100% of samples tested. The Buffer AVL plus ethanol and Buffer AVL plus heat treatments were also shown not to affect the extraction of PCR quality RNA from EBOV-spiked murine blood samples.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.